source
- Upcoming FDA decisions in Q3 2026 could signal agency flexibilityThe piece highlights five FDA actions slated for the third quarter of 2026 that industry participants are tracking. Observers say the outcomes may reveal how flexible the agency will be under its…
- Lilly's amylin-Zepbound combo shows 23% weight loss in type 2 diabetes patientsEli Lilly reported that its amylin‑Zepbound combination, eloraTZP, produced an average 23.3% weight loss in adults with type 2 diabetes who were also obese or overweight. The result was derived fro…